Ted Tisch, Janice Chen, Lucas Harrington, Trevor Martin and Peter Nell. (Mammoth)

Doud­na-found­ed CRISPR up­start bags $45M for new Cas re­search, ex­tends its reach in­to ther­a­peu­tics

The South San Fran­cis­co-based CRISPR up­start that set out to de­vel­op di­ag­nos­tics un­der co-founder Jen­nifer Doud­na’s guid­ance is back with $45 mil­lion in fund­ing — and new am­bi­tions in ther­a­peu­tics.

Mam­moth Bio­sciences is al­so putting its tech to the test amid height­ened vig­i­lance sur­round­ing the nov­el coro­n­avirus emerg­ing out of Wuhan, Chi­na. The goal is to pro­to­type a rapid mol­e­c­u­lar test that can be used at point of care.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.